CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,698,707 | -2.0% | 103,521 | +21.5% | 0.01% | -22.2% |
| Q2 2023 | $4,794,872 | +24.7% | 85,221 | +0.2% | 0.01% | +28.6% |
| Q1 2023 | $3,844,819 | +37.2% | 85,030 | +23.4% | 0.01% | +16.7% |
| Q4 2022 | $2,802,163 | -16.0% | 68,915 | +35.0% | 0.01% | -25.0% |
| Q3 2022 | $3,335,000 | +6.8% | 51,049 | +0.2% | 0.01% | +14.3% |
| Q2 2022 | $3,123,000 | +1.8% | 50,930 | -1.2% | 0.01% | +16.7% |
| Q1 2022 | $3,068,000 | -16.3% | 51,560 | +7.2% | 0.01% | -14.3% |
| Q4 2021 | $3,664,000 | -22.0% | 48,099 | +14.6% | 0.01% | -30.0% |
| Q3 2021 | $4,697,000 | -16.8% | 41,983 | +20.1% | 0.01% | -16.7% |
| Q2 2021 | $5,645,000 | +54.5% | 34,963 | +16.4% | 0.01% | +33.3% |
| Q1 2021 | $3,654,000 | +35.8% | 30,043 | +71.0% | 0.01% | +28.6% |
| Q4 2020 | $2,691,000 | +48.7% | 17,567 | -18.9% | 0.01% | +40.0% |
| Q3 2020 | $1,810,000 | +27.0% | 21,670 | +11.7% | 0.01% | 0.0% |
| Q2 2020 | $1,425,000 | +73.6% | 19,399 | +1.2% | 0.01% | +66.7% |
| Q1 2020 | $821,000 | – | 19,177 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |